NCT03645070

Brief Summary

It's a randomized pilot study to evaluate the incidence of esophageal thermal injury after left atrial ablation for the treatment of atrial fibrillation according to three different strategies of esophageal temperature monitoring. These patients will be divided into 3 groups with different strategies of esophageal temperature monitoring: group 1 without monitoring, group 2 monitoring with single probe thermometer and group 3 monitoring with multi-probe thermometer. The primary end point will be the incidence of esophageal lesions assessed by upper endoscopy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 11, 2017

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

August 22, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 24, 2018

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2018

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 24, 2020

Completed
Last Updated

January 10, 2022

Status Verified

January 1, 2022

Enrollment Period

1.2 years

First QC Date

August 22, 2018

Last Update Submit

January 6, 2022

Conditions

Keywords

atrial-esophageal fistularadiofrequency ablationAtrial Fibrillation ablation

Outcome Measures

Primary Outcomes (1)

  • Incidence of esophageal lesions

    Incidence of esophageal lesions evaluated by upper digestive endoscopy

    Within three days after the ablation procedure.

Secondary Outcomes (7)

  • Rate of recurrence of AF

    Six months

  • Isolation rate of pulmonary veins at the end of ablation.

    End of the procedure

  • Duration of the AF ablation procedure

    End of the procedure

  • Incidence of atrio-esophageal fistulas

    Six months

  • Difference in the size of the esophageal lesions

    Within three days

  • +2 more secondary outcomes

Study Arms (3)

No probe

NO INTERVENTION

Twenty patients will be allocated to this group, which will have no esophageal temperature monitoring technique

Single probe thermometer

ACTIVE COMPARATOR

Twenty patients will be allocated in this group, in which there will be monitoring of esophageal temperature during radiofrequency applications in the posterior wall of the left atrium, with unipolar thermometer.

Device: Single probe thermometer

Multi-probe

ACTIVE COMPARATOR

Twenty patients will be allocated in this group, in which there will be esophageal temperature monitoring during radiofrequency applications in the posterior wall of the left atrium, with a multipolar and self expandable thermometer.

Device: multipolar and self expandable thermometer

Interventions

Will be evaluated if a multipolar and self expandable thermometer is superior to no probe or to single probe thermometer at prevention of esophageal thermal injury.

Also known as: CIRCA's S-CATH™ Esophageal Temperature Monitoring System
Multi-probe

Will be evaluated if a single probe thermometer is superior to a multipolar and self expandable thermometer or to no probe thermometer at prevention of esophageal thermal injury

Single probe thermometer

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with paroxysmal or persistent AF, diagnosed by electrocardiogram, 24-hour Holter, or monitors of implantable or non-implantable events, with at least one episode of AF up to 12 months before the procedure. Patients should be willing and able to sign an informed consent form, and to undergo all procedures described in both the study protocol and the consent form.

You may not qualify if:

  • Atrial thrombus in the left atrium, history of AF ablation, history of cardiac surgery, contraindication to anticoagulation, permanent AF, New York Heart Association functional class III or IV, stroke in the last 3 months, pregnancy, history blood clotting abnormalities, previous oesophageal surgery, or advanced chronic kidney disease (creatinine \> 2.5 mg/dl).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Arrhythmia Clinical Unit - Instituto do Coração - HCFMUSP

São Paulo, São Paulo, 05403010, Brazil

Location

Related Publications (1)

  • Moura DMC, Pereira RAR, Pisani CF, Wu TC, Chokr MO, Hardy CA, Melo SL, Darrieux FCDC, Hachul DT, Scanavacca MI. Esophageal Temperature Monitoring during Atrial Fibrillation Ablation: A Randomized Study. Arq Bras Cardiol. 2025 Jun;122(7):e20250056. doi: 10.36660/abc.20250056. English, Portuguese.

MeSH Terms

Conditions

Arrhythmias, CardiacAtrial Fibrillation

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Mauricio I Scanavacca, MD, PhD

    Instituto do coração - HC/FMUSP

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Arrhythmia Clinical Unit Director

Study Record Dates

First Submitted

August 22, 2018

First Posted

August 24, 2018

Study Start

July 11, 2017

Primary Completion

October 1, 2018

Study Completion

July 24, 2020

Last Updated

January 10, 2022

Record last verified: 2022-01

Data Sharing

IPD Sharing
Will not share

Locations